About the Authors

Kay L Pogue-Geile, Ryan D George, David C Whitcomb
Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America

Ru Chen, Kara White Moyes, David A Crispin, Teresa A Brentnall
Department of Medicine, University of Washington, Seattle, Washington, United States of America

Mary P Bronner
Department of Pathology, Cleveland Clinic Foundation, Cleveland, Ohio, United States of America

Tatjana Crnogorac-Jurcevic, Sally Dowen
Molecular Oncology Unit, Cancer Research United Kingdom, Barts and the London School of Medicine and Dentistry, London, United Kingdom

Carol A Otey
Department of Cell and Molecular Physiology, University of North Carolina at Chapel Hill, North Carolina, United States of America

David C Whitcomb
Department of Cell Biology and Physiology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America

David C Whitcomb
Department of Human Genetics, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America

Corresponding Author

teribr@u.washington.edu

Competing Interests

TAB is in the process of filing a patent for the use of palladin as a marker for pancreatic cancer; KLPG, RC, DCW are participants in the same patent application.

Author Contributions

KLPG, RC, MPB, TCJ, CAO, DAC, DCW, and TAB designed the study. KLPG, RC, MPB, KWM, CAO, DAC, DCW, and TAB analyzed the data. MPB and TAB enrolled patients. KLPG, RC, MPB, KW, CAO, DAC, DCW, and TAB contributed to writing the paper. TAB, KWM, KLPG, RC, MPB, SD, and DAC collected data or did experiments for the study. KWM and RC performed PCR and sequence analysis of candidate genes, plasmid construction and HeLa cell culture and transfections. KLPG and RDG printed the microarray, hybridized RNA from pancreatic tissue samples to the customized microarray, and collected data.